How should upadacitinib be dosed, monitored, and what are its contraindications for adults with moderate-to-severe inflammatory diseases?

Upadacitinib Dosing, Monitoring, and Contraindications

Standard Dosing

Upadacitinib is dosed at 15 mg once daily for rheumatoid arthritis (RA), with higher doses of 30-45 mg used for inflammatory bowel disease (IBD) depending on disease phase. 1

Disease-Specific Dosing:

• Rheumatoid Arthritis/Psoriatic Arthritis: 15 mg once daily 1
• Ulcerative Colitis: 45 mg once daily for induction (8-16 weeks), then 15-30 mg once daily for maintenance 1, 2
• Crohn's Disease: 45 mg once daily for induction (12 weeks), then 15-30 mg once daily for maintenance (30 mg preferred for TNF-inhibitor failures) 1, 2
• Atopic Dermatitis: 15-30 mg once daily 3, 4
• Ankylosing Spondylitis: Effective at standard dosing based on phase 2 data 1

Critical Dosing Considerations:

• Food: Can be taken with or without food; high-fat meals increase AUC by 29% and Cmax by 39-60%, but this is not clinically significant 5
• Tablets must be swallowed whole; extended-release formulation requires intact administration 5

Drug Interactions Requiring Dose Adjustments

Strong CYP3A4 Inhibitors (e.g., Ketoconazole):

• Reduce upadacitinib dose when co-administered, as these increase upadacitinib exposure by 75% (AUC) and 70% (Cmax) 1, 5

Strong CYP3A4 Inducers (e.g., Rifampicin):

• Consider dose increase when rifampicin is used for latent TB prophylaxis or active TB treatment, as it reduces upadacitinib exposure by 61% (AUC) and 51% (Cmax) 1, 5

No Dose Adjustment Needed:

• Methotrexate, proton pump inhibitors, antacids, or CYP2D6 inhibitors 5

Organ Dysfunction Adjustments

Renal Impairment:

• Mild (eGFR 60-90 mL/min/1.73m²): No adjustment needed 5
• Moderate (eGFR 30-60 mL/min/1.73m²): No adjustment currently recommended for upadacitinib (unlike baricitinib) 1, 5
• Severe (eGFR 15-30 mL/min/1.73m²): Use with caution; exposure increases by 44% but no formal dose reduction established 5
• eGFR <15 mL/min: Not studied; avoid use 5

Hepatic Impairment:

• Mild (Child-Pugh A): No adjustment needed 1, 5
• Moderate (Child-Pugh B): Use with caution; exposure increases by 24-28% and Cmax by 43% 5
• Severe (Child-Pugh C): Contraindicated—do not use 1

Monitoring Requirements

Baseline Assessment:

• Complete blood count with differential (hemoglobin, absolute neutrophil count, absolute lymphocyte count) 1
• Liver function tests (transaminases) 1
• Renal function (creatinine/eGFR) 1
• Lipid panel 1
• Tuberculosis screening (latent and active) 1
• Hepatitis B and C screening 1

Follow-Up Monitoring Schedule:

• At 1 month and 3 months: Complete blood count, liver function tests, renal function 1
• Every 3 months thereafter: Complete blood count, liver function tests, renal function 1
• At 3 months only: Lipid panel (then manage per national guidelines if elevated) 1
• Disease activity: Assess regularly using validated composite measures (e.g., CDAI for RA, avoiding DAS28 as acute phase reactants are independently suppressed by JAK inhibitors) 1

Laboratory Thresholds for Dose Modification:

Hemoglobin:

• ≥90 g/L and ≤20 g/L decrease: Continue current dose 1
• <80 g/L or >20 g/L decrease (confirmed on repeat): Interrupt treatment until normalized 1

Absolute Neutrophil Count:

• >1000/mm³: Continue current dose 1
• 500-1000/mm³ on two sequential measures: Reduce dose or temporarily discontinue until >1000/mm³ 1

Absolute Lymphocyte Count:

• >750/mm³: Continue current dose 1
• 500-750/mm³ on two sequential measures: Reduce dose or temporarily discontinue until >750/mm³ 1
• <500/mm³: Significantly increases risk of opportunistic infections 1

Transaminases:

• Monitor periodically; manage elevations according to severity 1

Additional Safety Monitoring:

• Annual formal skin examination for non-melanoma skin cancer (NMSC), particularly given prior MTX and TNF inhibitor exposure 1
• Assess for herpes zoster risk: More frequent in higher-dose groups (45 mg and 30 mg) 1, 2

Absolute Contraindications

Severe Active Infections:

Do not initiate upadacitinib during active serious infections, including latent or active tuberculosis and opportunistic infections. 1

• Serious infection rates with upadacitinib are comparable to adalimumab at standard doses 1
• Special caution in patients ≥65 years with cardiovascular risk factors: Tofacitinib (class effect concern) showed higher serious infection rates versus TNF inhibitors in this population; use only if no alternative 1

Uncontrolled Malignancy:

• Active malignancy or ongoing chemotherapy (including checkpoint inhibitors): Contraindicated 1
• Prior malignancy: Requires shared decision-making considering timing (most trials excluded patients with malignancy within 5 years) 1
• No malignancy signal detected in registries or clinical trials to date 1

Severe Hepatic Disease:

• Child-Pugh C: Absolute contraindication 1

Pregnancy and Lactation:

• Contraception required for both female and male patients during treatment due to limited safety data 1
• Teratogenic in animal studies (rats and rabbits); affects parturition and peri/postnatal development 1

Common Pitfalls and Caveats

Loss of Response After Dose Reduction:

• In IBD, patients who lose response after reducing from 45 mg to 30 mg can often be recaptured with 45 mg reinduction 6
• Among those recaptured, 93.8% maintained remission on continued 45 mg versus only 21.1% who reduced to 30 mg again (p<0.001) 6
• Consider maintaining 45 mg in IBD patients who required this dose for initial response, particularly TNF-inhibitor failures 6

Acute Phase Reactant Suppression:

• CRP and ESR may decrease independently of true disease activity improvement 1
• Use disease activity scores that do not rely heavily on inflammatory markers (e.g., CDAI in RA rather than DAS28) 1

Gastrointestinal Perforation Risk:

• Rare but serious: 4 patients on 45 mg, 1 each on 30 mg and 15 mg in Crohn's disease trials 2
• Monitor for new abdominal symptoms, particularly in IBD patients 2

Dose-Dependent Adverse Events:

• Acne/rosacea: Most common adverse event (13.3-20.2 events per 100 patient-years for 15-30 mg doses) 3
• Herpes zoster: More frequent at higher doses (45 mg and 30 mg) 1, 2
• Hepatic disorders and neutropenia: More frequent with 30 mg maintenance dose 2
• Venous thromboembolism: Class effect concern, though rates ≤0.1 events per 100 patient-years in atopic dermatitis studies 3

Metabolism Considerations:

• 20% renal excretion, predominantly hepatic oxidation via CYP3A4 (minor CYP2D6 contribution) 1, 5
• Half-life 8-14 hours; steady-state achieved within 4 days 5
• 52% protein-bound; blood-to-plasma ratio of 1.0 5